Anticoagulation in a Faller with Atrial Fibrillation
An 82-year-old woman with atrial fibrillation, hypertension, diabetes, and heart failure lives alone. Her CHA2DS2-VASc score is 6 and HAS-BLED score is 4. She has had two mechanical falls in the past six months, neither causing fracture or intracranial bleeding; she takes aspirin 81 mg daily that she started herself. Her eGFR is 36 mL/min/1.73 m², weight 50 kg, and she has no prior major bleed. She is afraid of stroke but equally afraid of bleeding after a fall. The major direct oral anticoagulant trials enrolled few patients older than 80 with recurrent falls and severe renal impairment, and none compared a direct oral anticoagulant with aspirin. She asks, 'Wouldn't aspirin be safer for someone who falls?'
1. How would you estimate her absolute stroke and bleeding risks and frame the trade-off?
Read the worked answer
Her CHA2DS2-VASc score of 6 corresponds to a high annual ischemic stroke risk, commonly estimated at roughly 7-10% per year without anticoagulation. Her HAS-BLED score of 4 reflects hypertension, renal impairment, age, and aspirin use; it is a flag to identify and modify bleeding risk factors, not an automatic reason to withhold anticoagulation. Aspirin is not a safer substitute. It reduces stroke less than anticoagulation and still increases gastrointestinal and intracranial bleeding. To frame the trade-off, I would estimate that anticoagulation might reduce her annual ischemic stroke risk by about two-thirds, from roughly 8% to about 3%, while increasing major bleeding by a smaller absolute amount. The exact numbers depend on the baseline risk and the anticoagulant chosen. I would explain that a fall is a risk, but the absolute risk of intracranial hemorrhage per fall is low, and the stroke she is trying to avoid can be devastating. I would also address modifiable bleeding risks: avoid NSAIDs, control blood pressure, review fall risk, check vision and gait, and use the lowest appropriate anticoagulant dose.
2. How does the trial evidence apply to her, and what are the limits?
Read the worked answer
The direct oral anticoagulant trials established that these agents are at least as effective as warfarin for stroke prevention and generally cause less intracranial bleeding, but the trials underenrolled patients older than 80 with recurrent falls and severe renal impairment. Her eGFR of 36 means renal dosing must be checked carefully; for apixaban, for example, the reduced dose is used when two of three criteria are met: age 80 or older, weight 60 kg or less, and serum creatinine 1.5 mg/dL or higher. Her age and weight meet two criteria if her creatinine is also elevated, so the dose must be verified rather than assumed. The trials did not compare a direct oral anticoagulant with aspirin, so we cannot directly estimate the relative effect versus aspirin from those trials. We can reason from indirect evidence: aspirin is less effective for stroke prevention in atrial fibrillation and is not bleeds-free. Subgroup analyses generally show consistent benefit in older patients, but frail fallers are underrepresented. The evidence therefore supports anticoagulation as the default, with careful dose selection and shared decision-making rather than a claim that the trials perfectly represent her.
3. What recommendation and communication approach would you document?
Read the worked answer
I would recommend anticoagulation, likely a direct oral anticoagulant such as apixaban at the correctly verified dose, rather than aspirin. I would document that her stroke risk is high, that aspirin is not a safe substitute, and that her fall risk should be addressed concurrently. I would use shared decision-making: explain her estimated annual stroke risk, the expected relative and absolute reduction with anticoagulation, the bleeding risk, and the uncertainty introduced by her falls and renal impairment. I would ask what she fears most and what she values, and I would correct the misconception that aspirin is safer. I would involve a pharmacist for dose checking and drug interactions, a physical therapist for gait and balance, and a home safety assessment. I would document that she understands the trade-off and that either choice will be revisited if she has a serious fall or bleeding event. If she declines anticoagulation, I would document informed refusal, continue fall prevention, and avoid substituting aspirin as if it were equivalent. Follow-up should include renal function, hemoglobin, blood pressure, and adherence.